{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T04:17:37Z","timestamp":1728620257438},"posted":{"date-parts":[[2024,6,28]]},"group-title":"In Review","reference-count":66,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,6,7]]},"abstract":"<title>Abstract<\/title>\n        <p>Coxsackievirus B1 (CVB1) is a common cause of acute and chronic myocarditis, dilated cardiomyopathy and aseptic meningitis. However, no CVB-vaccines are available for human use. In this study, we investigated the immunogenicity of virus-like particle (VLP) and inactivated whole-virus vaccines for CVB1 when administrated to mice via either subcutaneous or intranasal routes formulated with and without commercial and experimental adjuvants. Here, the potential of utilizing epigallocatechin-3-gallate (EGCG) as a mucosal adjuvant synergistically with its ability to inactivate the virus were investigated. EGCG had promising adjuvant properties for CVB1-VLP when administered via the parenteral route but limited efficacy via intranasal administration. However, intranasal administration of the formalin-inactivated virus induced high CVB1-specific humoral, cellular, and mucosal immune responses. Also, based on CVB1-specific IgG-antibody responses, we conclude that CVB1-VLP can be taken up by immune cells when administrated intranasally and further structural engineering for the VLP may increase the mucosal immunogenicity. The preparations contained mixtures of compact and expanded A particles with 85% expanded in the formalin-inactivated virus, but only 52% in the VLP observed by cryogenic electron microscopy. To correlate the structure to immunogenicity, we solved the structures of the CVB1-VLP and the formalin-inactivated CVB1 virus at resolutions ranging from 2.15 \u00c5 to 4.1 \u00c5 for the expanded and compact VLP and virus particles by image reconstruction. These structures can be used in designing mutations increasing the stability and immunogenicity of CVB1-VLP in the future. Overall, our results highlight the potential of using formalin inactivated CVB1 vaccine in mucosal immunization programs and provide important information for future development of VLP-based vaccines against all enteroviruses.<\/p>","DOI":"10.21203\/rs.3.rs-4545395\/v1","type":"posted-content","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T18:56:30Z","timestamp":1719600990000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparison of structure and immunogenicity of CVB1-VLP and inactivated CVB1 vaccine candidates"],"prefix":"10.21203","author":[{"given":"Saana","family":"Soppela","sequence":"first","affiliation":[{"name":"Tampere University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zlatka","family":"Plavec","sequence":"additional","affiliation":[{"name":"University of Helsinki"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stina","family":"Gr\u00f6hn","sequence":"additional","affiliation":[{"name":"Tampere University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minne","family":"Jartti","sequence":"additional","affiliation":[{"name":"Tampere University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sami","family":"Oikarinen","sequence":"additional","affiliation":[{"name":"Tampere University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mira","family":"Laajala","sequence":"additional","affiliation":[{"name":"University of Jyv\u00e4skyl\u00e4"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varpu","family":"Marjom\u00e4ki","sequence":"additional","affiliation":[{"name":"University of Jyv\u00e4skyl\u00e4"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah J","family":"Butcher","sequence":"additional","affiliation":[{"name":"University of Helsinki"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minna M","family":"Hankaniemi","sequence":"additional","affiliation":[{"name":"Tampere University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/jmv.21998","article-title":"Coxsackievirus B3-associated aseptic meningitis: an emerging infection in Hong Kong","volume":"83","author":"Wong AH","year":"2011","unstructured":"Wong AH, Lau CS, Cheng PK, Ng AY, Lim WW. Coxsackievirus B3-associated aseptic meningitis: an emerging infection in Hong Kong. J Med Virol. 2011;83:483\u20139.","journal-title":"J Med Virol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1089\/vim.2004.17.358","article-title":"Coxsackievirus-induced pancreatitis","volume":"17","author":"Huber S","year":"2004","unstructured":"Huber S, Ramsingh AI. Coxsackievirus-induced pancreatitis. Viral Immunol. 2004;17:358\u201369.","journal-title":"Viral Immunol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/rmv.326","article-title":"The group B coxsackieviruses and myocarditis","volume":"11","author":"Kim KS","year":"2001","unstructured":"Kim KS, Hufnagel G, Chapman NM, Tracy S. The group B coxsackieviruses and myocarditis. Rev Med Virol. 2001;11:355\u201368.","journal-title":"Rev Med Virol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/317145a0","article-title":"Structure of a human common cold virus and functional relationship to other picornaviruses","volume":"317","author":"Rossmann MG","year":"1985","unstructured":"Rossmann MG, et al. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature. 1985;317:145\u201353.","journal-title":"Nature"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.chom.2021.01.001","article-title":"Cryo-EM structures reveal the molecular basis of receptor-initiated coxsackievirus uncoating","volume":"29","author":"Xu L","year":"2021","unstructured":"Xu L, et al. Cryo-EM structures reveal the molecular basis of receptor-initiated coxsackievirus uncoating. Cell Host Microbe. 2021;29:448\u2013e4625.","journal-title":"Cell Host Microbe"},{"key":"ref6","first-page":"167","volume-title":"Advances in Protein Chemistry","author":"Richardson JS","year":"1981","unstructured":"Richardson JS. The Anatomy and Taxonomy of Protein Structure. In: Anfinsen CB, Edsall JT, Richards FM, editors. Advances in Protein Chemistry. Volume 34. Academic; 1981. pp. 167\u2013339."},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/pro.5560031005","article-title":"Role and mechanism of the maturation cleavage of VP0 in poliovirus assembly: structure of the empty capsid assembly intermediate at 2.9 A resolution","volume":"3","author":"Basavappa R","year":"1994","unstructured":"Basavappa R, et al. Role and mechanism of the maturation cleavage of VP0 in poliovirus assembly: structure of the empty capsid assembly intermediate at 2.9 A resolution. Protein Sci. 1994;3:1651\u201369.","journal-title":"Protein Sci"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e0136722","DOI":"10.1128\/jvi.01367-22","article-title":"Structural Studies Reveal that Endosomal Cations Promote Formation of Infectious Coxsackievirus A9 A-Particles, Facilitating RNA and VP4 Release","volume":"96","author":"Domanska A","year":"2022","unstructured":"Domanska A, et al. Structural Studies Reveal that Endosomal Cations Promote Formation of Infectious Coxsackievirus A9 A-Particles, Facilitating RNA and VP4 Release. J Virol. 2022;96:e0136722.","journal-title":"J Virol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1016\/j.vaccine.2017.05.057","article-title":"Optimized production and purification of Coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model","volume":"35","author":"Hankaniemi MM","year":"2017","unstructured":"Hankaniemi MM, et al. Optimized production and purification of Coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model. Vaccine. 2017;35:3718\u201325.","journal-title":"Vaccine"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"eaaz2433","DOI":"10.1126\/sciadv.aaz2433","article-title":"A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates","volume":"6","author":"Stone VM","year":"2020","unstructured":"Stone VM, et al. A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates. Sci Adv. 2020;6:eaaz2433.","journal-title":"Sci Adv"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"5962","DOI":"10.1016\/j.vaccine.2019.08.037","article-title":"A comparative study of the effect of UV and formalin inactivation on the stability and immunogenicity of a Coxsackievirus B1 vaccine","volume":"37","author":"Hankaniemi MM","year":"2019","unstructured":"Hankaniemi MM, et al. A comparative study of the effect of UV and formalin inactivation on the stability and immunogenicity of a Coxsackievirus B1 vaccine. Vaccine. 2019;37:5962\u201371.","journal-title":"Vaccine"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"104595","DOI":"10.1016\/j.antiviral.2019.104595","article-title":"Formalin treatment increases the stability and immunogenicity of coxsackievirus B1 VLP vaccine","volume":"171","author":"Hankaniemi MM","year":"2019","unstructured":"Hankaniemi MM, et al. Formalin treatment increases the stability and immunogenicity of coxsackievirus B1 VLP vaccine. Antiviral Res. 2019;171:104595.","journal-title":"Antiviral Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8091287","article-title":"Structural Insight into CVB3-VLP Non-Adjuvanted Vaccine","volume":"8","author":"Hankaniemi MM","year":"2020","unstructured":"Hankaniemi MM, et al. Structural Insight into CVB3-VLP Non-Adjuvanted Vaccine. Microorganisms. 2020;8. 10.3390\/microorganisms8091287.","journal-title":"Microorganisms"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/hep.24610","article-title":"The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry","volume":"54","author":"Ciesek S","year":"2011","unstructured":"Ciesek S, et al. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology. 2011;54:1947\u201355.","journal-title":"Hepatology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/hep.24803","article-title":"-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry","volume":"55","author":"Calland N","year":"2012","unstructured":"Calland N, et al. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology. 2012;55:720\u20139.","journal-title":"Hepatology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.3748\/wjg.v17.i11.1507","article-title":"Epigallocatechin gallate inhibits HBV DNA synthesis in a viral replication - inducible cell line","volume":"17","author":"He W","year":"2011","unstructured":"He W, Li L-X, Liao Q-J, Liu C-L, Chen X-L. Epigallocatechin gallate inhibits HBV DNA synthesis in a viral replication - inducible cell line. World J Gastroenterol. 2011;17:1507\u201314.","journal-title":"World J Gastroenterol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0166-3542(93)90008-7","article-title":"Inhibition of the infectivity of influenza virus by tea polyphenols","volume":"21","author":"Nakayama M","year":"1993","unstructured":"Nakayama M, et al. Inhibition of the infectivity of influenza virus by tea polyphenols. Antiviral Res. 1993;21:289\u201399.","journal-title":"Antiviral Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1348-0421.2002.tb02724.x","article-title":"Additional inhibitory effect of tea extract on the growth of influenza A and B viruses in MDCK cells","volume":"46","author":"Imanishi N","year":"2002","unstructured":"Imanishi N, et al. Additional inhibitory effect of tea extract on the growth of influenza A and B viruses in MDCK cells. Microbiol Immunol. 2002;46:491\u20134.","journal-title":"Microbiol Immunol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1089\/acm.2006.12.669","article-title":"Gargling with tea catechin extracts for the prevention of influenza infection in elderly nursing home residents: a prospective clinical study","volume":"12","author":"Yamada H","year":"2006","unstructured":"Yamada H, Takuma N, Daimon T, Hara Y. Gargling with tea catechin extracts for the prevention of influenza infection in elderly nursing home residents: a prospective clinical study. J Altern Complement Med. 2006;12:669\u201372.","journal-title":"J Altern Complement Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1021\/jf901128u","article-title":"T.-Y. Antiviral effect of epigallocatechin gallate on enterovirus 71","volume":"57","author":"Ho H-Y","year":"2009","unstructured":"Ho H-Y, Cheng M-L, Weng S-F, Leu Y-L, Chiu D. T.-Y. Antiviral effect of epigallocatechin gallate on enterovirus 71. J Agric Food Chem. 2009;57:6140\u20137.","journal-title":"J Agric Food Chem"},{"key":"ref21","first-page":"1182","article-title":"Polyphenols Epigallocatechin Gallate and Resveratrol, and Polyphenol-Functionalized Nanoparticles Prevent Enterovirus Infection through Clustering and Stabilization of the Viruses","volume":"13","author":"Reshamwala D","year":"2021","unstructured":"Reshamwala D, et al. Polyphenols Epigallocatechin Gallate and Resveratrol, and Polyphenol-Functionalized Nanoparticles Prevent Enterovirus Infection through Clustering and Stabilization of the Viruses. Pharm 2021. 2021;13:1182.","journal-title":"Pharm 2021"},{"key":"ref22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.769088","article-title":"Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant","volume":"12","author":"Cheong Y","year":"2021","unstructured":"Cheong Y et al. Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant. Front Immunol 12, (2021).","journal-title":"Front Immunol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1586\/14760584.6.2.133","article-title":"New hepatitis B vaccine formulated with an improved adjuvant system","volume":"6","author":"Kundi M","year":"2007","unstructured":"Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines. 2007;6:133\u201340.","journal-title":"Expert Rev Vaccines"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/jmv.23903","article-title":"Coxsackievirus B1 reveals strain specific differences in plasmacytoid dendritic cell mediated immunogenicity","volume":"86","author":"H\u00e4m\u00e4l\u00e4inen S","year":"2014","unstructured":"H\u00e4m\u00e4l\u00e4inen S, et al. Coxsackievirus B1 reveals strain specific differences in plasmacytoid dendritic cell mediated immunogenicity. J Med Virol. 2014;86:1412\u201320.","journal-title":"J Med Virol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12250-020-00230-5","article-title":"On the Calculation of TCID50 for Quantitation of Virus Infectivity","volume":"36","author":"Lei C","year":"2020","unstructured":"Lei C, Yang J, Hu J, Sun X. On the Calculation of TCID50 for Quantitation of Virus Infectivity. Virol Sin. 2020;36:141\u20134.","journal-title":"Virol Sin"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin J","year":"2012","unstructured":"Schindelin J, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676\u201382.","journal-title":"Nat Methods"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nmeth.4169","article-title":"A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination","volume":"14","author":"Punjani A","year":"2017","unstructured":"Punjani A, Rubinstein JL, Fleet DJ, Brubaker M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat Methods. 2017;14:290\u20136.","journal-title":"Nat Methods"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jsb.2016.04.010","article-title":"Scipion: A software framework toward integration, reproducibility and validation in 3D electron microscopy","volume":"195","author":"Rosa-Trev\u00edn JM","year":"2016","unstructured":"de la Rosa-Trev\u00edn JM, et al. Scipion: A software framework toward integration, reproducibility and validation in 3D electron microscopy. J Struct Biol. 2016;195:93\u20139.","journal-title":"J Struct Biol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jsb.2012.09.006","article-title":"Implementation of a Bayesian approach to cryo-EM structure determination","volume":"180","author":"Scheres SHW","year":"2012","unstructured":"Scheres SHW, RELION. Implementation of a Bayesian approach to cryo-EM structure determination. J Struct Biol. 2012;180:519\u201330.","journal-title":"J Struct Biol"},{"year":"2016","author":"Kimanius D","key":"ref30","unstructured":"Kimanius D, Forsberg BO, Scheres SH, Lindahl E. Accelerated cryo-EM structure determination with parallelisation using GPUs in RELION-2. Elife 5, e18722 (2016)."},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e42166","DOI":"10.7554\/eLife.42166","article-title":"New tools for automated high-resolution cryo-EM structure determination in RELION-3","volume":"7","author":"Zivanov J","year":"2018","unstructured":"Zivanov J, et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. eLife. 2018;7:e42166.","journal-title":"eLife"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1042\/BCJ20210708","article-title":"W. New tools for automated cryo-EM single-particle analysis in RELION-4.0","volume":"478","author":"Kimanius D","year":"2021","unstructured":"Kimanius D, Dong L, Sharov G, Nakane T, Scheres SH. W. New tools for automated cryo-EM single-particle analysis in RELION-4.0. Biochem J. 2021;478:4169\u201385.","journal-title":"Biochem J"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jmb.2011.11.010","article-title":"A Bayesian View on Cryo-EM Structure Determination","volume":"415","author":"Scheres SHW","year":"2012","unstructured":"Scheres SHW. A Bayesian View on Cryo-EM Structure Determination. J Mol Biol. 2012;415:406\u201318.","journal-title":"J Mol Biol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/s41592-020-00990-8","article-title":"Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction","volume":"17","author":"Punjani A","year":"2020","unstructured":"Punjani A, Zhang H, Fleet DJ. Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction. Nat Methods. 2020;17:1214\u201321.","journal-title":"Nat Methods"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jmb.2003.07.013","article-title":"Optimal determination of particle orientation, absolute hand, and contrast loss in single-particle electron cryomicroscopy","volume":"333","author":"Rosenthal PB","year":"2003","unstructured":"Rosenthal PB, Henderson R. Optimal determination of particle orientation, absolute hand, and contrast loss in single-particle electron cryomicroscopy. J Mol Biol. 2003;333:721\u201345.","journal-title":"J Mol Biol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pro.3943","article-title":"UCSF ChimeraX: Structure visualization for researchers, educators, and developers","volume":"30","author":"Pettersen EF","year":"2021","unstructured":"Pettersen EF, et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci. 2021;30:70\u201382.","journal-title":"Protein Sci"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/pro.3235","article-title":"UCSF ChimeraX: Meeting modern challenges in visualization and analysis","volume":"27","author":"Goddard TD","year":"2018","unstructured":"Goddard TD, et al. UCSF ChimeraX: Meeting modern challenges in visualization and analysis. Protein Sci. 2018;27:14\u201325.","journal-title":"Protein Sci"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley P","year":"2010","unstructured":"Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010;66:486\u2013501.","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: a comprehensive Python-based system for macromolecular structure solution","volume":"66","author":"Adams PD","year":"2010","unstructured":"Adams PD, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr. 2010;66:213\u201321.","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1107\/S0907444909042073","article-title":"MolProbity: all-atom structure validation for macromolecular crystallography","volume":"66","author":"Chen VB","year":"2010","unstructured":"Chen VB, et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr. 2010;66:12\u201321.","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"534","DOI":"10.2144\/btn-2021-0022","article-title":"A simplified method for bronchoalveolar lavage in mice by orotracheal intubation avoiding tracheotomy","volume":"71","author":"Luckow B","year":"2021","unstructured":"Luckow B, Lehmann MH. A simplified method for bronchoalveolar lavage in mice by orotracheal intubation avoiding tracheotomy. Biotechniques. 2021;71:534\u20137.","journal-title":"Biotechniques"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s00125-017-4492-z","article-title":"A Coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of type 1 diabetes","volume":"61","author":"Stone VM","year":"2018","unstructured":"Stone VM, et al. A Coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of type 1 diabetes. Diabetologia. 2018;61:476\u201381.","journal-title":"Diabetologia"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.2337\/db21-0193","author":"Stone VM","year":"2021","unstructured":"Stone VM et al. Coxsackievirus B Vaccines Prevent Infection-Accelerated Diabetes in NOD Mice and Have No Disease-Inducing Effect. Diabetes db210193 (2021) 10.2337\/db21-0193."},{"key":"ref44","doi-asserted-by":"crossref","first-page":"11955","DOI":"10.1128\/JVI.01809-14","article-title":"Effect of Formaldehyde Inactivation on Poliovirus","volume":"88","author":"Wilton T","year":"2014","unstructured":"Wilton T, Dunn G, Eastwood D, Minor PD, Martin J. Effect of Formaldehyde Inactivation on Poliovirus. J Virol. 2014;88:11955\u201364.","journal-title":"J Virol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"e3000281","DOI":"10.1371\/journal.pbio.3000281","article-title":"A novel druggable interprotomer pocket in the capsid of rhino- and enteroviruses","volume":"17","author":"Abdelnabi R","year":"2019","unstructured":"Abdelnabi R, et al. A novel druggable interprotomer pocket in the capsid of rhino- and enteroviruses. PLoS Biol. 2019;17:e3000281.","journal-title":"PLoS Biol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-021-01779-x","article-title":"Identification of a conserved virion-stabilizing network inside the interprotomer pocket of enteroviruses","volume":"4","author":"Flatt JW","year":"2021","unstructured":"Flatt JW, Domanska A, Sepp\u00e4l\u00e4 AL, Butcher SJ. Identification of a conserved virion-stabilizing network inside the interprotomer pocket of enteroviruses. Commun Biol. 2021;4:1\u20138.","journal-title":"Commun Biol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"e1700324","DOI":"10.1002\/biot.201700324","article-title":"Virus-Like Particle Engineering: From Rational Design to Versatile Applications","volume":"13","author":"Ding X","year":"2018","unstructured":"Ding X, Liu D, Booth G, Gao W, Lu Y. Virus-Like Particle Engineering: From Rational Design to Versatile Applications. Biotechnol J. 2018;13:e1700324.","journal-title":"Biotechnol J"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/bit.25159","article-title":"Bioengineering virus-like particles as vaccines","volume":"111","author":"Lua LH","year":"2014","unstructured":"Lua LH, et al. Bioengineering virus-like particles as vaccines. Biotechnol Bioeng. 2014;111:425\u201340.","journal-title":"Biotechnol Bioeng"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"6642","DOI":"10.1016\/j.vaccine.2012.08.071","article-title":"A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge","volume":"30","author":"Liu Q","year":"2012","unstructured":"Liu Q, et al. A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine. 2012;30:6642\u20138.","journal-title":"Vaccine"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1016\/j.vaccine.2014.06.025","article-title":"A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice","volume":"32","author":"Ku Z","year":"2014","unstructured":"Ku Z, et al. A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice. Vaccine. 2014;32:4296\u2013303.","journal-title":"Vaccine"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.vaccine.2016.06.028","article-title":"Virus-like particle-based vaccine against coxsackievirus A6 protects mice against lethal infections","volume":"34","author":"Shen C","year":"2016","unstructured":"Shen C, et al. Virus-like particle-based vaccine against coxsackievirus A6 protects mice against lethal infections. Vaccine. 2016;34:4025\u201331.","journal-title":"Vaccine"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.antiviral.2016.02.011","article-title":"Coxsackievirus A16-like particles produced in Pichia pastoris elicit high-titer neutralizing antibodies and confer protection against lethal viral challenge in mice","volume":"129","author":"Zhang C","year":"2016","unstructured":"Zhang C, et al. Coxsackievirus A16-like particles produced in Pichia pastoris elicit high-titer neutralizing antibodies and confer protection against lethal viral challenge in mice. Antiviral Res. 2016;129:47\u201351.","journal-title":"Antiviral Res"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.vaccine.2015.03.034","article-title":"High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice","volume":"33","author":"Zhang C","year":"2015","unstructured":"Zhang C, et al. High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice. Vaccine. 2015;33:2335\u201341.","journal-title":"Vaccine"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.antiviral.2016.06.004","article-title":"Yeast-produced recombinant virus-like particles of coxsackievirus A6 elicited protective antibodies in mice","volume":"132","author":"Zhou Y","year":"2016","unstructured":"Zhou Y, et al. Yeast-produced recombinant virus-like particles of coxsackievirus A6 elicited protective antibodies in mice. Antiviral Res. 2016;132:165\u20139.","journal-title":"Antiviral Res"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.vaccine.2008.01.058","article-title":"Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge","volume":"26","author":"Chung Y-C","year":"2008","unstructured":"Chung Y-C, et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine. 2008;26:1855\u201362.","journal-title":"Vaccine"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1016\/j.vaccine.2013.05.019","article-title":"Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice","volume":"31","author":"Li H-Y","year":"2013","unstructured":"Li H-Y, Han J-F, Qin C-F, Chen R. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine. 2013;31:3281\u20137.","journal-title":"Vaccine"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"10445","DOI":"10.1007\/s00253-013-5257-3","article-title":"Virus-like particles produced in Saccharomyces cerevisiae elicit protective immunity against Coxsackievirus A16 in mice","volume":"97","author":"Zhao H","year":"2013","unstructured":"Zhao H, et al. Virus-like particles produced in Saccharomyces cerevisiae elicit protective immunity against Coxsackievirus A16 in mice. Appl Microbiol Biotechnol. 2013;97:10445\u201352.","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.vaccine.2017.12.057","article-title":"A virus-like particle vaccine confers protection against enterovirus D68 lethal challenge in mice","volume":"36","author":"Dai W","year":"2018","unstructured":"Dai W, et al. A virus-like particle vaccine confers protection against enterovirus D68 lethal challenge in mice. Vaccine. 2018;36:653\u20139.","journal-title":"Vaccine"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"10713","DOI":"10.1038\/s41598-018-28281-5","article-title":"A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge","volume":"8","author":"Lin Y-L","year":"2018","unstructured":"Lin Y-L, et al. A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge. Sci Rep. 2018;8:10713.","journal-title":"Sci Rep"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1016\/j.vaccine.2014.05.052","article-title":"A vesicular stomatitis virus-based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis","volume":"32","author":"Wu F","year":"2014","unstructured":"Wu F, Fan X, Yue Y, Xiong S, Dong C. A vesicular stomatitis virus-based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis. Vaccine. 2014;32:3917\u201326.","journal-title":"Vaccine"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1016\/j.vaccine.2004.03.033","article-title":"Intranasal delivery of chitosan\u2013DNA vaccine generates mucosal SIgA and anti-CVB3 protection","volume":"22","author":"Xu W","year":"2004","unstructured":"Xu W, et al. Intranasal delivery of chitosan\u2013DNA vaccine generates mucosal SIgA and anti-CVB3 protection. Vaccine. 2004;22:3603\u201312.","journal-title":"Vaccine"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1007\/s00705-019-04418-3","article-title":"Intranasal immunization with coxsackievirus A16 virus-like particles confers protection against lethal infection in neonatal mice","volume":"164","author":"Chen X","year":"2019","unstructured":"Chen X, et al. Intranasal immunization with coxsackievirus A16 virus-like particles confers protection against lethal infection in neonatal mice. Arch Virol. 2019;164:2975\u201384.","journal-title":"Arch Virol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"e0246422","DOI":"10.1371\/journal.pone.0246422","article-title":"Enzymatically polymerised polyphenols prepared from various precursors potentiate antigen-specific immune responses in both mucosal and systemic compartments in mice","volume":"16","author":"Tada R","year":"2021","unstructured":"Tada R, et al. Enzymatically polymerised polyphenols prepared from various precursors potentiate antigen-specific immune responses in both mucosal and systemic compartments in mice. PLoS ONE. 2021;16:e0246422.","journal-title":"PLoS ONE"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/imm.12614","article-title":"Vitamin A or E and a catechin synergize as vaccine adjuvant to enhance immune responses in mice by induction of early interleukin-15 but not interleukin\u20101\u03b2 responses","volume":"148","author":"Patel S","year":"2016","unstructured":"Patel S, et al. Vitamin A or E and a catechin synergize as vaccine adjuvant to enhance immune responses in mice by induction of early interleukin-15 but not interleukin\u20101\u03b2 responses. Immunology. 2016;148:352\u201362.","journal-title":"Immunology"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.chom.2022.08.001","article-title":"Structural basis for the synergistic neutralization of coxsackievirus B1 by a triple-antibody cocktail","volume":"30","author":"Zheng Q","year":"2022","unstructured":"Zheng Q, et al. Structural basis for the synergistic neutralization of coxsackievirus B1 by a triple-antibody cocktail. Cell Host Microbe. 2022;30:1279\u2013e12946.","journal-title":"Cell Host Microbe"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1101\/2023.01.30.526315","author":"Kingston NJ","year":"2023","unstructured":"Kingston NJ et al. Production of antigenically stable enterovirus A71 virus-like particles in Pichia pastoris as a vaccine candidate. bioRxiv 2023.01.30.526315 (2023) 10.1101\/2023.01.30.526315."}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4545395\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4545395\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T13:19:57Z","timestamp":1728566397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4545395\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":66,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-4545395\/v1","relation":{},"subject":[],"published":{"date-parts":[[2024,6,28]]},"subtype":"preprint"}}